When: Q3 organic revenue >+4% YoY AND Seagen ADC category signal vs Enhertu

Then: Upgrade to Overweight

When: Daily close below $25.50 (200 SMA break)

Then: Full Sell / Underweight

When: Dividend cut/freeze or further impairment >$3B

Then: Full Sell / Underweight

Trim 30-40% of position in scaled increments, maintain core holding for optionality, monitor dividend coverage trajectory through Q3 earnings, no new long positions at current levels

• Aggressive analyst conflates urgency with edge — risk reduction is not alpha generation
• AT&T comparison is flawed: PFE debt is from strategic acquisitions ($63B legacy), not distressed financing; management has 300-quarter dividend behavioral pattern
• 1.12x FCF coverage distorted by $4.99B Q2 working capital outflow from tax payments; annual FCF of $11B vs $9.8B dividends; dividend has glide path not binary
• 282% EPS expansion requirement is artifact of $4.33B Q2'26 impairments and $4.47B Q4'25 impairments; normalized EPS trajectory far less dramatic
• MACD histogram at minus 0.07 is noise; MACD line rising from 0.213 to 0.260 shows momentum reaccelerating
• Bollinger upper band tag at $28.94 is normal post-breakout price action from six-session consolidation, not short-term top signal
• Sub-average breakout volume normal in low-volatility regimes; 'quiet institutional engineering' equally plausible
• Traders 30-40% trim already correct shape — reduces exposure, locks in 23.9% one-year rally, preserves optionality
• LLY at 30x forward carries valuation risk; MRNA single-platform bet; PFE diversified across oncology (Seagen), vaccines (Comirnaty, XFG), internal medicine, I&I, rare disease
• 6.1% dividend yield and 0.30 beta attract income buyers when rates high — income investor marginal buyer supports stock
• Conservative path: trim measured, monitor Q3 earnings, reassess with fresh data not narrative risk

→ vs aggressive: AT&T precedent inapplicable — PFE debt from strategic acquisitions, not leverage event; management behavioral pattern of 300-quarter dividend prioritization

→ vs aggressive: 1.12x FCF coverage is distorted by one-time $4.99B working capital outflow from tax payments; normalized coverage meaningfully better

→ vs aggressive: 282% EPS expansion anchored on depressed TTM EPS; stripping $8.8B in non-cash impairments yields far less dramatic normalized trajectory

→ vs aggressive: MACD histogram at minus 0.07 is single-bar noise; MACD line rising 0.213 to 0.260 indicates momentum reaccelerating not failing

→ vs aggressive: Capital rotation thesis to LLY/MRNA ignores LLY valuation risk at 30x forward and MRNA single-platform concentration risk

→ vs aggressive: Hawkish regime argument conflates long-duration growth stocks with short-duration income equities; PFE attracts income buyers at 6.1% yield

→ vs aggressive: Full exit creates basis-point tracking error vs benchmark, removes diversification benefits, depends on dividend cut or downgrade with no fixed timing

→ vs aggressive: Value trap thesis based on forward multiple requires 282% EPS expansion — this is an artifact of impairment-distorted reported EPS, not normalized earnings power

Trim 30% of PFE position (not 40%), tighten entry zones to Bollinger upper band at $28.94 and swing high at $29.02, and define explicit re-entry triggers rather than executing a slow-motion exit

• GLP-1 structural gap is real—multi-year capital rotation toward LLY, MRNA, Viking is structural repricing, not a temporary trade
• 10-year yields at 2007 highs and 30-year at 2004 highs create income equity headwinds with no near-term catalyst for relief
• Dividend is a glide path deterioration over 3-6 quarters, not a binary announcement—management has multiple levers before cut (slower buybacks, CapEx deferral, divestitures)
• 282% EPS expansion is normalized recovery from artificially depressed base, not heroic growth projection; 9.8x forward multiple defensible on through-cycle earnings
• 30% trim captures bulk of risk reduction without creating benchmark drag or removing low-beta diversification benefit
• CDS and equity options markets not pricing imminent dividend cut—the aggressive's fear narrative lacks empirical support
• Income buyer bid is real but support level is below current price given thin 1.12x FCF coverage in high-rate refinancing environment
• MACD histogram still negative despite line rising from low base—pattern that precedes momentum rollover in late-stage trends
• Trimmed position preserves optionality for Q3/Q4 earnings to clarify dividend glide path and pipeline re-rating catalysts
• Stop loss at $29.50 as breakout-abort level provides correct asymmetry—trim into weakness, not strength

→ vs aggressive: The '1:1 risk-reward is a coin flip' framing misrepresents the trade—it's reducing exposure to deteriorated risk-adjusted return, not making a binary directional bet, and 'sell now or face 12% gap' has thin empirical base as CDS/options markets not pricing imminent cut

→ vs aggressive: Dividend is a glide path over 3-6 quarters, not a binary break-on-contact event—trade urgency overstated; real trade is 'trim now and reassess on Q3/Q4 earnings,' not panic exit

→ vs conservative: MACD 'reacceleration' reading is misleading—rising MACD line from low base while histogram is negative is the pattern preceding momentum rollover, not confirmed reversal

→ vs conservative: Income buyer bid conflates 'there is a bid' with 'bid holds current price'—support level likely lower given thin coverage and debt rolling into 2007-rate environment

→ vs conservative: Capital rotation is structural re-rating of growth optionality, not a trade—PFE's structural GLP-1 gap is permanent and can't be acquired without paying premium that compresses multiple